drugset / Trial / NCT02615574
A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The investigators hypothesize that the treatment of metastatic colorectal cancer (mCRC) patients with the combination of alpha-type-1-polarized dendritic cell (αDC1) vaccines and tumor-selective chemokine modulation (CKM) will promote the infiltration of vaccination-induced CD8+ CTLs to tumor lesions and subsequently tumor regression with improved patient survival.
Timeline
- Start
- 2016-03
- Primary completion
- 2018-06
- Completion
- 2018-12
Outcome
Outcome not reported
Stopped: “Due to inadequate supply of drug”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | — | — |
| Subject | INTERFERON ALFA-2B | Protein / enzyme biologic | — | — |
| Subject | Rintatolimod | Oligonucleotide (other) | — | — |
| Subject | αDC1 Vaccine | Vaccine | — | — |